Review of Drug Development Guidance to Treat Chronic Obstructive Pulmonary Disease: US and EU Perspectives

Autor: Lorcan McGarvey, Aernout D. van Haarst, Sabina Paglialunga

Publikováno v: van Haarst, A, McGarvey, L & Paglialunga, S 2019, ' Review of Drug Development Guidance to Treat Chronic Obstructive Pulmonary Disease: US and EU Perspectives ', Clinical Pharmacology and Therapeutics, vol. 106, no. 6, pp. 1222-1235 . https://doi.org/10.1002/cpt.1540
Clinical Pharmacology and Therapeutics

Chronic obstructive pulmonary disease (COPD) remains a leading cause of death worldwide, yet only one new drug class has been approved in the last decade. However, resurgence in COPD treatment has been recently fueled by a greater understanding of th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d3515cd580aef09d79b9a358e5bfba8
https://doi.org/10.1002/cpt.1540

Clinically Important Interaction Between Tedisamil and Verapamil

Autor: Aernout D. van Haarst, Jacobus Burggraaf, Adam F. Cohen, Hans-Josef Weimann, Rik C. Schoemaker, Anneke C. Dijkmans, Michiel J. B. Kemme, Jacobus J. Bosch

Publikováno v: The Journal of Clinical Pharmacology. 49:560-567

Tedisamil, a class III antiarrhythmic drug, is a P-glycoprotein substrate. Tedisamil treatment may implicate coadministration with class IV antiarrhythmics such as verapamil, a P-glycoprotein inhibitor. Pharmacokinetic and pharmacodynamic interaction

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2f77d38cd634feb0de612511a6a1fbb
https://doi.org/10.1177/0091270009332812

Effects of a nonpeptide motilin receptor antagonist on proximal gastric motor function

Autor: Ad A.M. Masclee, Ingrid M C Kamerling, Adam F. Cohen, Aernout D. van Haarst, Marieke L. de Kam, Hartmut Heinzerling, Jacobus Burggraaf, Rik C. Schoemaker

Publikováno v: British Journal of Clinical Pharmacology. 57:393-401

Aim To assess the effects of the motilin receptor antagonist RWJ-68023 on basal and motilin-stimulated proximal gastric volume. Methods Eighteen healthy male volunteers received RWJ-68023 in two different doses or placebo for 135 min. After 45 min, s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6d098c8e86e78ff60a42aa9ff35e52e1
https://doi.org/10.1046/j.1365-2125.2003.02034.x

Motilin effects on the proximal stomach in patients with functional dyspepsia and healthy volunteers

Autor: Rik C. Schoemaker, Adam F. Cohen, Izak Biemond, Ad A.M. Masclee, Aernout D. van Haarst, Ingrid M C Kamerling, Richard Jones, Jacobus Burggraaf, Hartmut Heinzerling

Publikováno v: American Journal of Physiology-Gastrointestinal and Liver Physiology. 284:G776-G781

This study investigates motilin effects on the proximal stomach in patients with functional dyspepsia (FD) and healthy volunteers. Eight healthy volunteers and 12 patients with FD were infused with synthetic motilin or placebo. Proximal gastric volum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79d689968ae01905fdd3c144b88ceff4
https://doi.org/10.1152/ajpgi.00456.2002

The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers

Autor: Adam F. Cohen, Michael R. Goldberg, Donald G. Musson, A. D. Van Haarst, M. E. De Puy, Kimberly L. Birk, Alison L Fisher, M De Smet, A. Sterrett, J.M.A. van Gerven

Publikováno v: British Journal of Clinical Pharmacology. 48:190-196

Aims The new 5-HT1B/1D agonist rizatriptan (MK-0462) has recently been registered for the treatment of migraine. Its primary route of metabolism is via monoamine oxidase-A (MAO-A). Antidepressants such as the MAO-A inhibitor moclobemide may be used i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9db5595bc887b8b14cd60f3d79ff168c
https://doi.org/10.1046/j.1365-2125.1999.00011.x